Literature DB >> 14999695

MELD score as a predictor of pretransplant and posttransplant survival in OPTN/UNOS status 1 patients.

Walter K Kremers1, Marrije van IJperen, W Ray Kim, Richard B Freeman, Ann M Harper, Patrick S Kamath, Russell H Wiesner.   

Abstract

The Model for End-Stage Liver Disease (MELD) score is predictive of survival and is used to prioritize patients with chronic liver disease patients for orthotopic liver transplantation (OLT). The aims of this study are (1) to assess the ability of MELD score at listing to predict pretransplant and posttransplant survival for nonchronic liver disease patients listed with the Organ Procurement and Transplantation Network/ United Network for Organ Sharing (OPTN/UNOS) as Status 1; and (2) to compare survival associated with 4 diagnostic groups within the Status 1 designation. The study population consisted of adult patients listed for OLT at Status 1 in the UNOS national database between November 1, 1999 and March 14, 2002 (N = 720). Events within 30 days of listing were analyzed using Kaplan-Meier and Cox regression methodology. Patients meeting criteria for fulminant hepatic failure without acetaminophen toxicity (FHF-NA, n = 312) had the poorest survival probability while awaiting OLT; this was negatively correlated with MELD score (P =.0001). These patients experienced the greatest survival benefit associated with OLT, with an estimated improvement of survival from about 58% to 91% (P <.0001). Patients listed for primary nonfunction within 7 days of OLT (n = 268) did not show mortality to be related to MELD score (P =.41) and did not show a significant association between survival and OLT (P =.68). In conclusion, liver allocation within the Status 1 designation may need to be further stratified by diagnosis, and MELD score may be useful for prioritizing FHF-NA candidates.

Entities:  

Mesh:

Year:  2004        PMID: 14999695     DOI: 10.1002/hep.20083

Source DB:  PubMed          Journal:  Hepatology        ISSN: 0270-9139            Impact factor:   17.425


  44 in total

1.  Development of a survival evaluation model for liver transplant recipients with hepatocellular carcinoma secondary to hepatitis B.

Authors:  Ming Zhang; Bo Li; Lu-Nan Yan; Fei Yin; Tian-Fu Wen; Yong Zeng; Ji-Chun Zhao; Yu-Kui Ma
Journal:  World J Gastroenterol       Date:  2008-02-28       Impact factor: 5.742

2.  Epistaxis in end stage liver disease masquerading as severe upper gastrointestinal hemorrhage.

Authors:  Marine Camus; Dennis M Jensen; Jason D Matthews; Gordon V Ohning; Thomas O Kovacs; Rome Jutabha; Kevin A Ghassemi; Gustavo A Machicado; Gareth S Dulai
Journal:  World J Gastroenterol       Date:  2014-10-14       Impact factor: 5.742

3.  End-stage liver disease patients with MELD >40 have higher waitlist mortality compared to Status 1A patients.

Authors:  Joseph Ahn; Taft Bhuket; Sasan Mosadeghi; Catherine Frenette; Benny Liu; Robert J Wong
Journal:  Hepatol Int       Date:  2016-05-24       Impact factor: 6.047

Review 4.  Model for End-stage Liver Disease.

Authors:  Ashwani K Singal; Patrick S Kamath
Journal:  J Clin Exp Hepatol       Date:  2012-12-01

5.  Adult-to-adult living donor liver transplantation for acute liver failure in China.

Authors:  Ding Yuan; Fei Liu; Yong-Gang Wei; Bo Li; Lv-Nan Yan; Tian-Fu Wen; Ji-Chun Zhao; Yong Zeng; Ke-Fei Chen
Journal:  World J Gastroenterol       Date:  2012-12-28       Impact factor: 5.742

6.  Management of hepatic encephalopathy.

Authors:  Jennifer A Frontera
Journal:  Curr Treat Options Neurol       Date:  2014-06       Impact factor: 3.598

Review 7.  Predictive factors of short term outcome after liver transplantation: A review.

Authors:  Giuliano Bolondi; Federico Mocchegiani; Roberto Montalti; Daniele Nicolini; Marco Vivarelli; Lesley De Pietri
Journal:  World J Gastroenterol       Date:  2016-07-14       Impact factor: 5.742

8.  Waitlist Outcomes of Liver Transplant Candidates Who Were Reprioritized Under Share 35.

Authors:  E K H Chow; A B Massie; X Luo; C E Wickliffe; S E Gentry; A M Cameron; D L Segev
Journal:  Am J Transplant       Date:  2016-08-24       Impact factor: 8.086

9.  Recipient ineligibility after liver transplantation assessment: a single centre experience.

Authors:  Aman Arya; Roberto Hernandez-Alejandro; Paul Marotta; Julia Uhanova; Natasha Chandok
Journal:  Can J Surg       Date:  2013-06       Impact factor: 2.089

10.  Caspofungin for post solid organ transplant invasive fungal disease: results of a retrospective observational study.

Authors:  M Winkler; J Pratschke; U Schulz; S Zheng; M Zhang; W Li; M Lu; D Sgarabotto; G Sganga; P Kaskel; S Chandwani; L Ma; J Petrovic; M Shivaprakash
Journal:  Transpl Infect Dis       Date:  2010-01-11       Impact factor: 2.228

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.